Welcome to NexBio

Our Mission

Our mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening human diseases.

NexBio is recipient of the 4th Annual “Scientific American 50” Award for a medical treatment. Prior award winners include Genentech, IDEC Pharmaceuticals, and Vertex Pharmaceuticals.
(click the icon on right for the press release)

NexBio is proudly listed as one of the Life Science Partners - a collaboration between the San Diego Natural History Museum and the BIOCOM Institute - in Celebration of Darwin’s 200th Birthday. (click Darwin's image on right to see Nexbio's name association with this celebration)

Fludase®

Fludase® is in clinical development as a first-in-class broad-spectrum prophylactic and therapeutic agent for Influenza-Like Illness caused by all annual and pandemic variations of influenza virus (IFV), including Pandemic Influenza A(H1N1) and avian H5N1, as well as parainfluenza. Fludase® is currently undergoing a Phase II clinical trial for the treatment of community acquired influenza.

Corporate Profile

Scientist NexBio is a San Diego based company in operation since 2003. NexBio is the recipient of five NIH grants totaling $14M and a BAA contract for $49.5M. NexBio’s lead product, Fludase^®, is currently undergoing Phase II clinical development (click here for detailed information on the trial). NexBio is performing lead optimization of a second novel protein therapeutic, Sepcidin™. NexBio has also invented TOSAP^® a proprietary microparticle formulation technology used for its compounds, as well as those of its partners.

Pandemic Influenza

As the world braces for a global influenza pandemic, NexBio feels a strong social responsibility to protect human lives by advancing its anti-influenza medication Fludase® as quickly and safely as possible.

Below is a map provided by the U.S. Department of Health and Human Services, showing the ongoing 2009-10 influenza activity in the U.S. caused by both seasonal and pandemic H1N1 strains. History tells us the this pandemic may circle the globe more than once.